Clinical study
The natural history of stroke in sickle cell disease

https://doi.org/10.1016/0002-9343(78)90772-6Get rights and content

Abstract

The occurrence and progression of strokes in patients with sickle cell disease and the resultant structural and functional defects were investigated by an indepth study of 35 patients, 32 of whom are part of a natural history study of 537 patients. The relative frequency for all ages is 6 per cent. Strokes are predominantly seen in patients with sickle cell anemia (33 with sickle cell anemia and two with heterozygous hemoglobin S and C (SC) disease). Twenty-five of the patients were less than 20 years old at the time of the first stroke—9.1 per cent of all patients observed during this age range. The actuarial or predictive risk of an initial stroke during the first two decades is 0.761 episodes per 100 person years whereas after age 20 the risk is 0.524 episodes per 100 person years. Children significantly at risk (p < 0.01) for cerebral infarction have a mean age at onset of 7.7 years (modal age of 5 years). Contrarily, adults have a significant risk for intracranial hemorrhage (p < 0.05). Five of the 23 patients who had a cerebral infarct died. No predictive factors such as prior illness rate, hemoglobin level, fetal hemoglobin content or previous neurologic symptoms identified the patient “at risk” prior to the first stroke. Follow-up of the patients with cerebral infarction for a mean observation time of nine years revealed a reoccurrence rate of 67 per cent. Temporal clustering of the recurrence within 36 months is the outstanding clinical feature of this group of patients, and 80 per cent of subsequent strokes occurred before 36 months. Each patient who survived showed a functional neurologic improvement immediately after the stroke but never regained the intellectual or neurologic status they had before the stroke. Residual neurologic deficit increased with each reoccurrence and 11 of the patients have permanent paralysis. Computerized tomography demonstrated structural damage with low density areas in all patients with cerebral infarcts. These patients were not treated with a transfusion program of antisickling agents. Subarachnoid or intracerebral hemorrhage occurred in 11 young adults ages 14 to 36 years, all with SS. Six of the 11 died, and structural vascular defects such as aneurysms were found in four. The susceptible person with SS experiences a definitive period of risk marked by recurrent stroke episodes following which no further strokes are likely to occur. Factors contributing to this cessation are unknown.

References (39)

  • D Richards et al.

    Angiographic media and the sickling phenomena

  • JA Stockman et al.

    Occlusions of large cerebral vessels in sickle cell anemia

    N Engl J Med

    (1972)
  • JM Lusher et al.

    A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction

    Am J Hematol

    (1976)
  • BA Portnoy et al.

    Neurological manifestations in sickle cell disease

    Ann Intern Med

    (1972)
  • RL Baird et al.

    Studies in sickle cell anemia. XXI. Clinico-pathological aspects of neurological manifestations

    Pediatrics

    (1964)
  • A Adeloye et al.

    The nervous system in sickle cell disease

    Afr J Med

    (1970)
  • ML Falter et al.

    Massive intracranial hemorrhage in sickle cell anemia

    Am J Dis Child

    (1973)
  • J Allen et al.

    Neurological impairment induced by hyperventilation in children with sickle cell anemia

    Pediatrics

    (1976)
  • L Boros et al.

    Large cerebral vessel disease in sickle cell anemia

    J Neurol, Neurosurg, Psychiatry

    (1976)
  • Cited by (531)

    • Global burden of transfusion in sickle cell disease

      2023, Transfusion and Apheresis Science
    View all citing articles on Scopus

    This study was supported by Grant HL 15162, National Heart, Lung and Blood Institute.

    1

    From the Department of Pediatrics, University of Southern California School of Medicine, Los Angeles County-USC Medical Center, and the Comprehensive Sickle Cell Center, Los Angeles, California.

    View full text